Aptose to Participate in Upcoming Investor Conferences In March 2018
SAN DIEGO and TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming conferences:
- Cowen and Company 38th Annual Healthcare Conference
| Time: | 12:00 p.m. EDT | ||
| Date: | Monday, March 12, 2018 | ||
| Location: | The Boston Marriott Copley Place, Boston, MA | ||
| Live webcast: | http://wsw.com/webcast/cowen46/apto/ | ||
- 30th Annual ROTH Conference
| Time: | 9:30 a.m. PDT | ||
| Date: | Tuesday, March 13, 2018 | ||
| Location: | The Ritz Carlton, Laguna Niguel, CA | ||
| Live webcast: | http://wsw.com/webcast/roth32/apto/ | ||
- 2018 B. Riley & Co. China Healthcare Investment Partnering Symposium
| Time: | 11:30 a.m. CST (China Standard Time) | ||
| Date: | Friday, March 16, 2018 | ||
| Location: | The Intercontinental Hotel, Hangzhou, People’s Republic of China | ||
| Live webcast: | http://wsw.com/webcast/brileyco20/apto/ | ||
- Oppenheimer 28th Annual Healthcare Conference
| Time: | 8:00 a.m. EDT | ||
| Date: | Wednesday, March 21, 2018 | ||
| Location: | The Westin Grand Central, New York, NY | ||
| Live webcast: | https://veracast.com/webcasts/opco/healthcare2018/76201109497.cfm | ||
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: gchow@aptose.com
|
SMP Communications Susan Pietropaolo 201-923-2049 susan@smpcommunications.com |
LifeSci Advisors Michael Wood Managing Director 646-597-6983 mwood@lifesciadvisors.com |
Released March 6, 2018